Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
तुलना करने के लिए मीट्रिक्स | TENX | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधTENXपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −9.5x | −5.1x | −0.5x | |
PEG अनुपात | −0.10 | 0.02 | 0.00 | |
क़ीमत/बुक | 2.1x | 2.7x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 27.8x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 201.7% | 145.7% | 45.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | 9.2% | 6.9% | अनलॉक करें |